Document:

Exhibit

Praxair, Inc. and Subsidiaries
	
	
	 

EXHIBIT 10.05c

SECOND AMENDMENT TO THE
PRAXAIR, INC.
SUPPLEMENTAL RETIREMENT INCOME PLAN A
(EFFECTIVE JANUARY 1, 2008)
Article III, Section 3 of the Praxair, Inc. Supplemental Retirement Income Plan A (Effective January 1, 2008) is hereby amended, effective as of February 28, 2017, to amend and restate the first paragraph thereof in its entirety as follows:

“In the event of a Change in Control, all SRIP A Benefits not yet paid under this Plan shall become immediately vested and shall be paid in a lump sum payment, calculated as otherwise described herein, as soon as administratively possible following the date of such Change in Control, but no later than 90 days after such date.  Notwithstanding any provision of this Plan to the contrary, a Participant (including a Participant who has previously separated from service and is receiving payment of his or her SRIP A Benefit) who satisfies criteria established by the Committee or the Corporation’s Chief Human Resources Officer (the “CHRO”), as determined in the sole discretion of the Committee or the CHRO, may elect, at the time and in the manner designated by the Committee or the CHRO, to waive the right to receive payment of his or her unpaid SRIP A Benefit upon a Change in Control and such waiver shall be considered the deletion of such Participant’s Change in Control payment event as contemplated under Treasury Regulation Section 1.409A-2(b)(6).  Any Participant who makes such election shall receive payment of his or her SRIP A Benefits at such time and in such manner as otherwise provided under the Plan.  Any such election must be consistent with the election made by the Participant with respect to his or her benefits, if any, under the EPB and/or SRIP B, and shall be valid if, and only if, made at least one year prior to the effective date of any Change in Control.  For this purpose, “Change in Control” shall mean the occurrence of any one of the following events with respect to the Corporation:”

PRAXAIR, INC.

By:_________________________________
     Vice President, 
Chief Human Resources Officer

Date:________________________________Exhibit

Praxair, Inc. and Subsidiaries
	
	
	 

EXHIBIT 10.05g

THIRD AMENDMENT TO THE
PRAXAIR, INC.
SUPPLEMENTAL RETIREMENT INCOME PLAN B
(AS AMENDED AND RESTATED EFFECTIVE DECEMBER 31, 2007)
Article III, Section 3 of the Praxair, Inc. Supplemental Retirement Income Plan B (As Amended and Restated Effective December 31, 2007) is hereby amended, effective as of February 28, 2017, to amend and restate the first paragraph thereof in its entirety as follows:

“In the event of a Change in Control, all SRIP B Benefits not yet paid under this Plan shall become immediately vested and shall be paid in a lump sum payment, calculated as otherwise described herein, as soon as administratively possible following the date of such Change in Control, but no later than 90 days after such date.  Notwithstanding any provision of this Plan to the contrary, a Participant (including a Participant who has previously separated from service and is receiving payment of his or her SRIP B Benefit) who satisfies criteria established by the Committee or the Corporation’s Chief Human Resources Officer (the “CHRO”), as determined in the sole discretion of the Committee or the CHRO, may elect, at the time and in the manner designated by the Committee or the CHRO, to waive the right to receive payment of his or her unpaid SRIP B Benefit upon a Change in Control and such waiver shall be considered the deletion of such Participant’s Change in Control payment event as contemplated under Treasury Regulation Section 1.409A-2(b)(6).  Any Participant who makes such election shall receive payment of his or her SRIP B Benefits at such time and in such manner as otherwise provided under the Plan.  Any such election must be consistent with the election made by the Participant with respect to his or her benefits, if any, under the EPB and/or SRIP A, and shall be valid if, and only if, made at least one year prior to the effective date of any Change in Control.  For this purpose, “Change in Control” shall mean the occurrence of any one of the following events with respect to the Corporation:”

PRAXAIR, INC.

By:_________________________________
     Vice President, 
Chief Human Resources Officer

Date:________________________________Exhibit

Praxair, Inc. and Subsidiaries
	
	
	 

EXHIBIT 10.05j

SECOND AMENDMENT TO THE
PRAXAIR, INC.
EQUALIZATION BENEFIT PLAN
(AS AMENDED AND RESTATED EFFECTIVE DECEMBER 31, 2007)
Article III, Section 3 of the Praxair, Inc. Equalization Benefit Plan (As Amended and Restated Effective December 31, 2007) is hereby amended, effective as of February 28, 2017, to amend and restate the first paragraph thereof in its entirety as follows:

“In the event of a Change in Control, all EBP Benefits not yet paid under this Plan shall become immediately vested and shall be paid in a lump sum payment, calculated as otherwise described herein, as soon as administratively possible following the date of such Change in Control, but no later than 90 days after such date.  Notwithstanding any provision of this Plan to the contrary, a Participant (including a Participant who has previously separated from service and is receiving payment of his or her EPB Benefit) who satisfies criteria established by the Committee or the Corporation’s Chief Human Resources Officer (the “CHRO”), as determined in the sole discretion of the Committee or the CHRO, may elect, at the time and in the manner designated by the Committee or the CHRO, to waive the right to receive payment of his or her unpaid EBP Benefit upon a Change in Control and such waiver shall be considered the deletion of such Participant’s Change in Control payment event as contemplated under Treasury Regulation Section 1.409A-2(b)(6).  Any Participant who makes such election shall receive payment of his or her EBP Benefits at such time and in such manner as otherwise provided under the Plan.  Any such election must be consistent with the election made by the Participant with respect to his or her benefits, if any, under the SRIP A and/or SRIP B, and shall be valid if, and only if, made at least one year prior to the effective date of any Change in Control.  For this purpose, “Change in Control” shall mean the occurrence of any one of the following events with respect to the Corporation:”

PRAXAIR, INC.

By:_________________________________
     Vice President, 
Chief Human Resources Officer

Date:________________________________Exhibit

Praxair, Inc. and Subsidiaries
	
	
	 

EXHIBIT 10.07a

FIRST AMENDMENT
TO THE 
PRAXAIR COMPENSATION DEFERRAL PROGRAM

Section 5.1(f) of the Praxair Compensation Deferral Program, Amended and Restated as of July 15, 2014, is hereby amended in its entirety, effective as of February 28, 2017, as set forth below:

“(f)    Notwithstanding any provision in this Plan to the contrary, all Praxair Contributions shall fully vest and each Participant shall receive a lump sum payment of his or her entire benefit under this Plan (and any election to receive installment payments shall be disregarded) at such time as the Board determines that a Change in Control has occurred.  Such payment shall be made in full within 45 days after the Change in Control; provided, however, that a Participant who satisfies criteria established by the Committee or the Corporation’s Chief Human Resources Officer (the “CHRO”), as determined in the sole discretion of the Committee or the CHRO, may elect, at the time and in the manner designated by the Committee or the CHRO, to waive the right to receive a lump sum payment of his or her entire Plan benefit upon a Change in Control and such waiver shall be considered the deletion of such Participant’s Change in Control payment event as contemplated under Treasury Regulation Section 1.409A-2(b)(6).  Any Participant who makes such election shall receive payment of his or her Plan benefit at such time and in such form as otherwise provided under the Plan.  Any such election shall be valid if, and only if, made at least one year prior to the effective date of any Change in Control, and shall not count as a subsequent election as described in Section 5.5.”

PRAXAIR, INC.

By:_________________________________
     Vice President, 
Chief Human Resources Officer

Date:______________________________ex10-25.htm

THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [***] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 

Exhibit 10.20

SECOND AMENDMENT TO DISTRIBUTORSHIP AGREEMENT

 

THIS SECOND AMENDMENT to Distributorship Agreement (“Second Amendment”) is made this 3 day of November, 2016 by and between Oxford Immunotec Limited, a company incorporated in England with number 04516079, whose registered office is at 94C Innovation Drive, Milton Park, Abingdon, Oxfordshire OX154 4RZ (the “Company”) and Fosun Long March Medical Science Co. Ltd., (registration number Shanghai Joint-Venture 000422) whose registered office and principal place of business is both at 830 Cheng Yin Road, Shanghai, China 200444 (“Fosun Shanghai I) and Shanghai Xin Chang Medical Device Co. Ltd (registration number 310110000477786), whose registered office and principal place of business is at number 830 Cheng Yin Road, Shanghai, China 200444 (“Fosun Shanghai II”) (Fosun Shanghai I and Fosun Shanghai II are herein collectively referred to as “Distributors”.)

 

Whereas,

 

A.     The Company and Distributors are parties to a Distributorship Agreement dated 8 October 2013 (the “Distributorship Agreement”), and amended on or about 22 April 2015 (the “First Amendment”), pursuant to which Distributors were appointed to distribute Company’s Products in the Territory; and,

 

B.     The Company and Distributors now wish to further amend the Distributorship Agreement to incorporate the terms and conditions as set forth in this Second Amendment.

 

IT IS AGREED as follows:

 

1.     Except to the extent defined in this Amendment, all capitalized terms shall have the definitions provided in the Distributorship Agreement. 

 

2.     The Parties agree that Schedule 1 to the Distributorship Agreement as set forth in the First Amendment shall be amended by deleting Subparagraph B in its entirety and replacing it with the following: 

 

B.     No Charge Kit Program for 2016

 

1.     OI agrees to provide up to [***] Kits to Distributors at no charge in 2016 for Distributors’ use in connection with Distributors promotional and discount programs (the “No Charge Kits”) so long as Distributor purchases a total of [***] Kits on or before [***] (the “2016 Sales Target”). Unless otherwise agreed by the parties, the No Charge Kits shall be delivered by OI in coordination with OI’s shipment of Kits purchased by Distributors in amounts proportionate to the purchased Kits. 

 

2.     If the 2016 Sales Target is not met as set forth above, OI shall invoice, and Distributors shall remit payment for, the No Charge Kits at the Agreed Price of Kits.

 

 

 

 

 

THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [***] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 

Exhibit 10.20

  

3.     Except as amended hereby, all other terms of the Distributorship Agreement shall remain in full force and effect. 

 

IN WITNESS that this Amendment has been executed by duly authorized officers of the parties to the Agreement the day and year first above written.

 

For and on behalf of Oxford Immunotec Limited

 

	Signature:	
  /s/ Peter Wrighton-Smith 
	
 

	 	
 
	
 

	Name:	
Dr. Peter Wrighton-Smith
	
 

	 	
 
	
 

	Title:	
CEO
	
 

	 	
 
	
 

	Date:	
14 October 2016 
	
 

	 	
 
	
 

	Place:	
Oxford Immunotec Office, UK 
	
 

 

 

  

For and on behalf of Shanghai Fosun Long March Medical Science Co. Ltd.

 

 

	Signature:	  /s/ Zhu Yao Yi	
 

	 	
 
	
 

	Name:	Mr Zhu Yao Yi	
 

	 	
 
	
 

	Title:	Chairman	
 

	 	
 
	
 

	Date:	03 November 2016	
 

	 	
 
	
 

	Place:	Fosun, China	
 

  

  

For and on behalf of Shanghai Xin Chang Medical Device Co. Ltd.

 

 

	Signature:	  /s/ Zhu Yao Yi	
 

	 	
 
	
 

	Name:	Mr Zhu Yao Yi	
 

	 	
 
	
 

	Title:	Chairman	
 

	 	
 
	
 

	Date:	03 November 2016	
 

	 	
 
	
 

	Place:	Fosun, China	
 

 

 

2

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00267-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00267-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00267-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00267-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00267-of-00352.parquet"}]]